First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Median PFS appears to back earlier response rate promise.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Solstice Oncology acquires porustobart from Harbour Biomed.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
2026’s first big oncology buyout is here.
